563 related articles for article (PubMed ID: 23901037)
1. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
[TBL] [Abstract][Full Text] [Related]
3. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
4. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
[TBL] [Abstract][Full Text] [Related]
5. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
[TBL] [Abstract][Full Text] [Related]
6. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
[TBL] [Abstract][Full Text] [Related]
7. Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6.
Bourhis E; Wang W; Tam C; Hwang J; Zhang Y; Spittler D; Huang OW; Gong Y; Estevez A; Zilberleyb I; Rouge L; Chiu C; Wu Y; Costa M; Hannoush RN; Franke Y; Cochran AG
Structure; 2011 Oct; 19(10):1433-42. PubMed ID: 21944579
[TBL] [Abstract][Full Text] [Related]
8. Peptide-based mediated disruption of N-cadherin-LRP5/6 interaction promotes Wnt signaling and bone formation.
Haÿ E; Buczkowski T; Marty C; Da Nascimento S; Sonnet P; Marie PJ
J Bone Miner Res; 2012 Sep; 27(9):1852-63. PubMed ID: 22576936
[TBL] [Abstract][Full Text] [Related]
9. LRP6 mediates Wnt/β-catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells.
Peröbner I; Karow M; Jochum M; Neth P
Int J Biochem Cell Biol; 2012 Nov; 44(11):1970-82. PubMed ID: 22871567
[TBL] [Abstract][Full Text] [Related]
10. Heterozygosity for an inactivating mutation in low-density lipoprotein-related receptor 6 (Lrp6) increases osteoarthritis severity in mice after ligament and meniscus injury.
Joiner DM; Less KD; Van Wieren EM; Hess D; Williams BO
Osteoarthritis Cartilage; 2013 Oct; 21(10):1576-85. PubMed ID: 23756208
[TBL] [Abstract][Full Text] [Related]
11. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
12. N-cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6-PTH1R interaction.
Yang H; Dong J; Xiong W; Fang Z; Guan H; Li F
Ann N Y Acad Sci; 2016 Dec; 1385(1):41-52. PubMed ID: 27723935
[TBL] [Abstract][Full Text] [Related]
13. Application of anti-Sclerostin therapy in non-osteoporosis disease models.
Jacobsen CM
Bone; 2017 Mar; 96():18-23. PubMed ID: 27780792
[TBL] [Abstract][Full Text] [Related]
14. Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.
Sato AY; Cregor M; Delgado-Calle J; Condon KW; Allen MR; Peacock M; Plotkin LI; Bellido T
J Bone Miner Res; 2016 Oct; 31(10):1791-1802. PubMed ID: 27163932
[TBL] [Abstract][Full Text] [Related]
15. Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts.
Goel S; Chin EN; Fakhraldeen SA; Berry SM; Beebe DJ; Alexander CM
J Biol Chem; 2012 May; 287(20):16454-66. PubMed ID: 22433869
[TBL] [Abstract][Full Text] [Related]
16. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.
Semënov M; Tamai K; He X
J Biol Chem; 2005 Jul; 280(29):26770-5. PubMed ID: 15908424
[TBL] [Abstract][Full Text] [Related]
17. Insights into the mechanisms of sclerostin action in regulating bone mass accrual.
Williams BO
J Bone Miner Res; 2014 Jan; 29(1):24-8. PubMed ID: 24285419
[No Abstract] [Full Text] [Related]
18. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
[TBL] [Abstract][Full Text] [Related]
19. Genetic deletion of low-density lipoprotein receptor-related protein 5 increases cartilage degradation in instability-induced osteoarthritis.
Lodewyckx L; Luyten FP; Lories RJ
Rheumatology (Oxford); 2012 Nov; 51(11):1973-8. PubMed ID: 22850184
[TBL] [Abstract][Full Text] [Related]
20. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.
van Dinther M; Zhang J; Weidauer SE; Boschert V; Muth EM; Knappik A; de Gorter DJ; van Kasteren PB; Frisch C; Mueller TD; ten Dijke P
PLoS One; 2013; 8(4):e62295. PubMed ID: 23638027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
